Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | GPR132 | Q9UNW8 | 5/20 | 0.39 |
| ▸ | CCKBR | P32239 | 1/20 | 0.38 |
| ▸ | HPGDS | O60760 | 2/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | CMKLR2 | P46091 | 1/20 | 0.37 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18180172 | 0.93 | ALDH1A1 (0.46) | PYGLALDH1A1RAB9AGPR132HPGDS | |
| SCHEMBL18180219 | 0.93 | ALDH1A1 (0.46) | PYGLALDH1A1RAB9AGPR132HPGDS | |
| SCHEMBL19962038 | 0.91 | PIN1 (0.39) | PYGLALDH1A1RAB9ACCKBRMRGPRX4 | |
| SCHEMBL28632707 | 0.91 | ALDH1A1 (0.44) | PYGLALDH1A1RAB9AGPR132HPGDS | |
| SCHEMBL28636566 | 0.91 | ALDH1A1 (0.44) | PYGLALDH1A1RAB9AGPR132HPGDS | |
| SCHEMBL19962066 | 0.90 | PYGL (0.41) | PYGLALDH1A1RAB9ACCKBRHPGDS | |
| SCHEMBL30534188 | 0.88 | ALDH1A1 (0.47) | PYGLALDH1A1RAB9AGPR132HPGDS | |
| SCHEMBL29067348 | 0.88 | ALDH1A1 (0.47) | PYGLALDH1A1RAB9AGPR132HPGDS | |
| SCHEMBL19962039 | 0.85 | PYGL (0.41) | PYGL | |
| SCHEMBL19962069 | 0.84 | PYGL (0.37) | PYGLRAB9ACCKBRHPGDSPIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180072997-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072997-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR2H, POLR2E | PYGL 498/4885ALDH1A1 2545/4885RAB9A 1767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.